List of Tables
Summary Table: Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 1: Global Incidence of All Cancers, by WHO Region, 2022-2050
Table 2: Global Incidence of Leukemia, by WHO Region, 2022-2050
Table 3: Global Incidence of Hodgkin Lymphoma, by WHO Region, 2022-2050
Table 4: Global Incidence of Non-Hodgkin Lymphoma, by WHO Region, 2022-2050
Table 5: Global Incidence of Multiple Myeloma, by WHO Region, 2022-2050
Table 6: Patents Held by Oxford Biomedica, 2021-Present
Table 7: Selected Patents Held by Lonza, 2021-Present
Table 8: Patents Held by Regenxbio, 2021-Present
Table 9: Selected Clinical Trials, by Viral Vector Type
Table 10: Global Market for Viral Vector and Plasmid DNA Technologies, Through 2028
Table 11: Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 12: Global Market for Plasmid DNA Technology, by Region, Through 2028
Table 13: Global Market for Viral Vector Technology, by Region, Through 2028
Table 14: Global Market for Viral Vector and Plasmid DNA Technologies, by End User, Through 2028
Table 15: Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, Through 2028
Table 16: Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, by Region, Through 2028
Table 17: Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, Through 2028
Table 18: Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, by Region, Through 2028
Table 19: Global Market for Viral Vector and Plasmid DNA Technologies, by Application, Through 2028
Table 20: Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 21: Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Region, Through 2028
Table 22: North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 23: North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 24: Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 25: Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 26: European Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 27: European Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 28: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 29: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 30: RoW Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 31: Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 32: Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Region, Through 2028
Table 33: North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 34: North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 35: Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 36: Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 37: European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 38: European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 39: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 40: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 41: RoW Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 42: Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 43: Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Region, Through 2028
Table 44: North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 45: North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 46: Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 47: Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 48: European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 49: European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 50: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 51: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 52: RoW Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 53: Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 54: Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Region, Through 2028
Table 55: North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 56: North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 57: Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 58: Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 59: European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 60: European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 61: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 62: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 63: RoW Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 64: Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 65: Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Region, Through 2028
Table 66: North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 67: North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 68: Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 69: Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 70: European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 71: European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 72: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 73: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country/Region, Through 2028
Table 74: RoW Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 75: Global Market for Viral Vector and Plasmid DNA Technologies, by Region, Through 2028
Table 76: North American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 77: North American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 78: Latin American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 79: Latin American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 80: European Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 81: European Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 82: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 83: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 84: RoW Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 85: ESG Rankings of Major Companies, 2024*
Table 86: Lonza: ESG Performance
Table 87: Thermo Fisher Scientific Inc.: ESG Performance
Table 88: Acronyms Used in This Report
Table 89: Agilent Technologies Inc.: Company Snapshot
Table 90: Agilent Technologies Inc.: Financial Performance, FY 2021 and 2022
Table 91: Agilent Technologies Inc.: Product Portfolio
Table 92: Agilent Technologies Inc.: News/Key Developments, 2023
Table 93: Bluebird Bio Inc.: Company Snapshot
Table 94: Bluebird Bio Inc.: Financial Performance, FY 2021 and 2022
Table 95: Bluebird Bio Inc.: Product Portfolio
Table 96: Bluebird Bio Inc.: Key News/Developments, 2022
Table 97: Catalent Inc.: Company Snapshot
Table 98: Catalent Inc.: Financial Performance, FY 2021 and 2022
Table 99: Catalent Inc.: Product Portfolio
Table 100: Catalent Inc.: Key News/Developments, 2021-2024
Table 101: Danaher Corp.: Company Snapshot
Table 102: Danaher Corp.: Financial Performance, FY 2021 and 2022
Table 103: Danaher Corp.: Product Portfolio
Table 104: Danaher Corp.: News/Key Developments, 2022
Table 105: Fujifilm Holdings Corp.: Company Snapshot
Table 106: Fujifilm Holdings Corp.: Financial Performance, FY 2021 and 2022
Table 107: Fujifilm Holdings Corp.: Product Portfolio
Table 108: Fujifilm Holdings Corp.: News/Key Developments, 2022
Table 109: GenScript: Company Snapshot
Table 110: GenScript: Financial Performance, FY 2021 and 2022
Table 111: GenScript: Product Portfolio
Table 112: GenScript: News/Key Developments, 2023
Table 113: Gilead Sciences Inc.: Company Snapshot
Table 114: Gilead Sciences Inc.: Financial Performance, FY 2021 and 2022
Table 115: Gilead Sciences Inc.: Product Portfolio
Table 116: Gilead Sciences Inc.: News/Key Developments, FY 2021-2022
Table 117: Lonza: Company Snapshot
Table 118: Lonza: Financial Performance, FY 2021 and 2022
Table 119: Lonza: Product Portfolio
Table 120: Lonza: News/Key Developments, FY 2022
Table 121: Novartis AG: Company Snapshot
Table 122: Novartis AG: Financial Performance, FY 2021 and 2022
Table 123: Novartis AG: Product Portfolio
Table 124: Novartis AG: News/Key Developments, FY 2022
Table 125: Oxford Biomedica Plc: Company Snapshot
Table 126: Oxford Biomedica Plc: Financial Performance, FY 2021 and 2022
Table 127: Oxford Biomedica Plc: Product Portfolio
Table 128: Oxford Biomedica Plc: News/Key Developments, FY 2022
Table 129: PlasmidFactory GmbH: Company Snapshot
Table 130: PlasmidFactory GmbH: Product Portfolio
Table 131: Regenxbio Inc.: Company Snapshot
Table 132: Regenxbio Inc: Financial Performance, FY 2021 and 2022
Table 133: Regenxbio Inc: Product Portfolio
Table 134: Regenxbio Inc.: News/Key Developments, FY 2022
Table 135: Thermo Fisher Scientific Inc.: Company Snapshot
Table 136: Thermo Fisher Scientific Inc.: Financial Performance, FY 2021 and 2022
Table 137: Thermo Fisher Scientific Inc.: Product Portfolio
Table 138: VGXI Inc.: Company Snapshot
Table 139: VGXI Inc.: Product Portfolio
List of Figures
Summary Figure A: Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, 2020-2028
Summary Figure B: Global Market Shares of Viral Vector and Plasmid DNA Technologies, by Product Type, 2022
Figure 1: Viral Vector and Plasmid DNA Technologies: Market Dynamics
Figure 2: Approved Cell and Gene Therapy Product Count, 2003 to the Present
Figure 3: Emerging Trends/Technologies in Viral Vector and Plasmid DNA Technologies
Figure 4: Global Company Market Shares of Viral Vector and Plasmid DNA Technologies, 2022
Figure 5: Global Company Market Shares of Viral Vectors, 2022
Figure 6: Global Company Market Shares of Plasmid DNA, 2022
Figure 7: Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2022
Figure 8: Agilent Technologies Inc.: Revenue Share, by Region, FY 2022
Figure 9: Catalent Inc.: Revenue Share, by Business Unit, FY 2022
Figure 10: Catalent Inc.: Revenue Share, by Country/Region, FY 2022
Figure 11: Danaher Corp.: Revenue Share, by Business Unit, FY 2022
Figure 12: Danaher Corp.: Revenue Share, by Country/Region, FY 2022
Figure 13: Fujifilm Holdings Corp.: Revenue Share, by Business Unit, FY 2022
Figure 14: Fujifilm Holdings Corp.: Revenue Share, by Country/Region, FY 2022
Figure 15: GenScript: Revenue Share, by Business Unit, FY 2022
Figure 16: GenScript: Revenue Share, by Country/Region, FY 2022
Figure 17: Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2022
Figure 18: Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2022
Figure 19: Lonza: Revenue Share, by Business Unit, FY 2022
Figure 20: Lonza: Revenue Share, by Country/Region, FY 2022
Figure 21: Novartis AG: Revenue Share, by Business Unit, FY 2022
Figure 22: Novartis AG: Revenue Share, by Country/Region, FY 2022
Figure 23: Oxford Biomedica Plc: Revenue Share, by Business Unit, FY 2022
Figure 24: Oxford Biomedica Plc: Revenue Share, by Country/Region, FY 2022
Figure 25: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2022
Figure 26: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2022
